Strongbridge Biopharma PLC (NASDAQ:SBBP) posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34), MarketWatch Earnings reports. The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.84 million.
Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) opened at 7.05 on Friday. The firm has a 50-day moving average price of $6.98 and a 200 day moving average price of $4.80. The stock’s market cap is $249.11 million. Strongbridge Biopharma PLC has a 52 week low of $2.00 and a 52 week high of $8.85.
Several research analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price objective on the stock. Zacks Investment Research cut shares of Strongbridge Biopharma PLC from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. ValuEngine upgraded shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, HC Wainwright restated a “buy” rating on shares of Strongbridge Biopharma PLC in a research report on Wednesday, May 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $11.94.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/strongbridge-biopharma-plc-nasdaqsbbp-releases-earnings-results-hits-expectations-updated.html.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
What are top analysts saying about Strongbridge Biopharma PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Strongbridge Biopharma PLC and related companies.